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To investigate the antiangiogenic potential of encapsulated VEGF165b producing HEK293 cells, Human Embryonic Kidney 293
(HEK293) cells were stably transfected to produce VEGF165b. Then they were encapsulated in alginate - polylysine -alginate (APA)
microcapsules. VEGF165b productivity and viability of encapsulated cells were analyzed and compared with the non-encapsulated
cells. Results showed that encapsulated cells proliferated and remained viable within the microcapsules throughout the 28-day
period of the experiment. The quantity of VEGF165b increased from 6.5 ± 1.2μg/ml at day 13 to 13 ± 0.96μg/ml at day 16. Then
it gradually dropped to 5 ± 1.2μg/ml for the last 3 days period as measured at day 28. Production of VEGF165b from encapsulated
and non-encapsulated cells was similar. The eﬀe c to fV E G F 165b harvested from encapsulated cells on Human Umbilical Vein
Endothelial cells (HUVECs) proliferation were also examined.The same inhibitory eﬀects on HUVECs proliferation was seen
when the cells were incubated with a mixture of VEGF165b and a 2-fold VEGF165bo rw i t hV E G F 165b and 2-fold excess VEGF165b
released from encapsulated cells. Subcutaneous injection of microencapsulated VEGF165b producing cells in tumor site of nude
mice resulted in the reduction of the number of vessels around the tumors.
1.Introduction
Vascular endothelial growth factor (VEGF) is a prominent
growth factor and a key regulator of normal and patho-
physiological angiogenesis [1, 2]. VEGF is a multifunctional
glycoprotein that stimulates endothelial cell migration and
proliferation, increases vascular permeability, and protects
endothelial cells from apoptosis [3]. VEGF expression is
upregulated in the majority of human cancers and it is
considered as an important target for anticancer therapy [4,
5].Overexpressionofangiogenicfactorsgeneratestheimbal-
ance between angiogenesis regulators and inhibitors and
stimulates endothelial cell activation which leads to angio-
genic switch and consequently allows the tumor to access
a nutrition source essential for its growth and metastasis
[6, 7].
Among VEGF isoforms, VEGF165 is the most commonly
detected isoform and the predominant growth factor and
plays a fundamental role in tumor angiogenesis [8]. The
angiogenesis eﬀects of VEGF165 appear to be mediated
mainly by activation of VEGF receptor 2 (VEGFR-2).
VEGF165 can be inhibited by its own counterpart VEGF165b.
VEGF165b is one of VEGF isoforms that inhibits VEGF165-
mediated signaling by acting as a competitive antagonist
of VEGFR2. VEGF165b does not stimulate VEGFR-2 phos-
phorylation in the same manner as VEGF165 and inhibits
VEGF-dependent angiogenesis. Hence, this VEGF isoform
can be a potential therapeutic protein for antiangiogenic
therapy in tumor suppression [9–12]. To develop a system,
continuously producing this protein, we considered using
engineered cells to supply a stable source of protein,
encapsulate the engineered cells to protect them from host
immune system and implant the encapsulated producing
cells in vivo. Microencapsulation of cells provides a safe
environment for the recombinant cells to be able to survive,
proliferate, and produce the desired protein in spite of the2 Journal of Biomedicine and Biotechnology
presence of host immune mediators, which are responsible
for graft rejection [13, 14]. This protection is achievable
via a permselective membrane of the microcapsule that
eliminates eﬀects of host immune system and provides free
access of nutrients and oxygen for implanted encapsulated
cells [15, 16]. We hypothesized that microencapsulation of
engineered cells stably producing VEGF165b and implanting
the encapsulated cells in tumor-site would provide clinical
beneﬁts by reducing tumor mediated angiogenesis and
preventing the tumor converting from a dormant lesion to a
rapidly enlarging metastatic mass [17].
In this study, for the ﬁrst time, APA microencapsulated
VEGF165bp r o d u c i n gH E K 2 9 3c e l l sh a v eb e e nu s e dt o
provide continuous source of VEGF165b for antiangiogenic
therapy using various in vitro procedures. The antiangiogen-
esis preclinical eﬃcacy of VEGF165b released from micro-
capsules containing HEK293 VEGF165b producing cells was
investigated in nude mice.
2.MaterialsandMethods
2.1. Cell Line. The human embryonic kidney 293 cell
line, stably expressing Epstein-Barr virus Nuclear Antigen-1
(clone 6E), was grown as a suspension culture in FreeStyle
or Freestyle-F17 (F17; Invitrogen) medium, a serum- and
protein-free medium, supplemented with 0.1% pluronic F-
68 and 50μg/ml Geneticin. Cells were grown agitated at
110rpm at 37
◦C in a humidiﬁed 5% CO2 chamber and
routinely passed in 125-ml Erlenmeyer ﬂasks containing
20ml of culture medium.
An ELISA was carried out to measure the quantity of
VEGF165bharvestedfromencapsulatedVEGF165bproducing
cells and nonencapsulated VEGF165b producing cells. The
quantity of VEGF165b increased from 6.5 ± 1.2μg/ml at day
13 to 13 ± 0.96μg/ml at day 16. The level of VEGF165b
then gradually dropped to 5 ± 1.2μg/ml for the last 3 days
period. The highest quantity of VEGF165bs e c r e t e df r o m
nonencapsulated cells was 14.2 ± 0.84 and 15 ± 1.8a td a y
16 and 19, respectively. The values then dropped to 7±0.8a t
day 28 (Figure 3).
2.2. Plasmid Construction and Puriﬁcation. The human
codon-optimized VEGF165b cDNA (Geneart) was inserted
between the EcoRI and BamHI sites of the pYD7 vector
(pTT vector bearing a blasticidin resistance expression
cassette) [18–20]. E. coli DH5α grown in Circle Growth
broth supplemented with ampicillin (100μg/ml) was used to
amplify the plasmid, which was puriﬁed using a Maxiprep
plasmid puriﬁcation kit (Qiagen, Valencia, CA). Plasmid
DNA concentration was measured at 260nm following its
dilution in 50mM Tris-HCl, pH 8.0. Plasmid DNA was
then linearized by PvuI digestion for stable integration into
chromosomal DNA.
2.3. Transfection, Selection, and Clone Isolation. The trans-
fection method was performed using previously established
procedure [18, 21]. Brieﬂy, the cells were seeded at 1 ×
106 cells/ml before transfection. DNA was diluted in fresh
serum-free medium in a volume of one-tenth of the culture
to be transfected at a concentration of 1.0μg/ml. PEI [22]
(branched 25kDa, Aldrich) was added at a ratio of 1:1.5
(DNA:PEI). The mixture was vortexed and incubated at
room temperature for 15 minutes. It was then added to
the cells in a Nunclon Surface plate and incubated at 37
◦C
and agitated at 110rpm for one hour. The cells were then
plated as 0.3 × 106 cells/well in a 6-well CellBind plate and
incubated at 37
◦C. Blasticidin was added at 24 hours post
transfection at a concentration of 1μg/ml. After 2 weeks of
selection with regular medium changes, blasticidin-resistant
cells were plated in CellBind 96-well plates at a density of
1 cell per well in 200μl FreeStyle media supplemented with
50% conditioned media, 0.05% TN1, and phenol red. Each
well was visually examined the day after plating and those
containing a single cell were identiﬁed. Half of the medium
was replaced by fresh medium every 10 days. After 20–
30 days, the presence of VEGF165b in the culture medium
was analyzed by western blot. The wells containing the cells
producing high amount of VEGF165b were identiﬁed and
the cells were ampliﬁed. In order to select the best clone,
cells were seeded in a 6-well plate at the concentration of
0.5×106 cells/wellandincubatedat37
◦Cinahumidiﬁed 5%
CO2 chamber. Five days later, the cells were counted and the
supernatant was analyzed by western blot for the presence
of VEGF165b. The clone with best growth rate and highest
amount of protein production was selected (clone F10).
2.4. Microencapsulation of Transfected Cells. Microencapsu-
lation of HEK293 VEGF165b producing cells (clone F10) was
performed as described previously with slight modiﬁcation
[23–27]. Cells were centrifuged at 1000g for 10min. The
supernatant was decanted and the cells were resuspended in
25±5ml sterile-ﬁltered 1.65% (w/v) alginate (obtained from
Sigma-Aldrich, low viscosity) solution in 0.85% (w/v) saline
to give 1 × 106 cells/ml. The mixture of cells and alginate
solution was loaded in a 60ml syringe and extruded through
an Inotech Encapsulator IER-20 (Inotech Biosystems Inter-
national,Rockville,MD)witha300μmnozzleatafrequency
of1052Hzandavoltageof1.0kV.Alginatedropletswerecol-
lected in 1.5% CaCl2 solution and the gelation process took
place for 30 minutes. To prepare APA microcapsules, Ca-
alginate beads were immersed in a 0.1% (w/v) poly-l-lysine
(Sigma, MW 27400) solution in 0.85% (w/v) saline for 15
minutes followed by a 10-minute incubation in a 0.1% (w/v)
alginate solution in 0.85% (w/v) saline. The ﬁnal microcap-
sules were transferred to the same media used for nonencap-
sulated cells and stored at 37
◦C for further analysis.
2.5. Monitoring Metabolic Activity of Encapsulated Cells. The
metabolic activity and cell proliferation of encapsulated
cells were determined using an MTS colorimetric assay
(Promega).Theassayisbasedontheabilityofdehydrogenase
enzymes found in metabolically active cells to convert MTS
into a formazan product that is soluble in culture medium.
The quantity of formazan product as measured by the
amount of 490nm absorbance is directly proportional to the
number of living cells in culture.Journal of Biomedicine and Biotechnology 3
The assay was performed according to previously de-
scribed procedures with slight modiﬁcations [28–30]. Every
three days, approximately 50 ± 5 microcapsules were trans-
ferredtoa96-wellplateandincubatedwith100μlmediaand
20μlM T S / P M Ss o l u t i o na t3 7
◦C for 4 hours. The optical
density was read and recorded at 490nm using a plate reader.
Thecellswerequantiﬁedusingacalibrationcurvecorrelating
cell number with absorbance. The metabolic activity of
nonencapsulated cells was also determined using the same
protocol. An equivalent number of nonencapsulated cells
were plated in a 96-well plate and every three days their
metabolic activity was determined. The cell number was
obtained using a calibration curve correlating cell quantity
with absorbance.
2.6. Western Blot Analysis of Protein Productivity of Encapsu-
lated Cells. Sodium dodecyl sulfate-polyacrylamide gel elec-
trophoresis (SDS-PAGE) and western blot were performed
according to standard procedure to verify the protein pro-
duction of microencapsulated 293/IFNα cells. Encapsulated
cells were suspended in F17 medium and incubated at 37
◦C
in a humidiﬁed 5% CO2 chamber. The medium was replaced
every three days and analyzed by western blot for the pres-
enceofVEGF165b.Theharvestedmediumfromencapsulated
cells was diluted in NuPAGE 4X sample buﬀer (Invitrogen,
Carlsbad, CA) containing 50mM DTT and then heated at
70
◦C for 10min. Separation was performed on NuPAGE
4–12% Bis-Tris gel (Invitrogen, Carlsbad, CA) using MES
running buﬀer for 40min at 200V. Western blots were per-
formed by transferring proteins to nitrocellulose membrane
using Tris-glycine buﬀer for 1 hour at 300mA. The mem-
brane was then incubated with a rabbit antihuman VEGF
(R&D) diluted 1:500 for 1 hour followed by incubation with
an antirabbit horseradish peroxidase (1:5000) for 1 hour.
The blots were revealed using a BM Chemiluminescent Blot-
ting kit (Roche). The same procedure was performed for free
nonencapsulated cells to compare VEGF165bp r o d u c t i v i t yt o
encapsulated cells by plating an equivalent number of cells in
a 96-well plate. The medium was replaced every three days
and analyzed by western blot for the presence of VEGF165b.
2.7. VEGF165bQ u a n t i ﬁ c a t i o n . The VEGF165b concentration
in conditioned media of encapsulated cells was determined
with an enzyme-linked immunosorbent assay (ELISA) fol-
lowing the protocol supplied by the Human VEGF ELISA kit
(DVE00, R&D).
2.8. In Vitro Bioactivity Assay of VEGF165b, HUVECs Pro-
liferation. The eﬀects of VEGF and VEGF165b on HUVECs
proliferation were evaluated as described previously [31–33].
HUVECs were seeded as 5000 cells/well in a 96-well plate.
The cells were serum- and growth factors-starved overnight.
Thecellswerethendividedinto3groups,onegroupreceived
diﬀerent concentration of VEGF, and the other two groups
receivedVEGFwithtwo-folddilutionseriesofeitherpuriﬁed
VEGF165bo rV E G F 165b collected from supernatant of the
encapsulated cells. HUVEC proliferation was determined
after 72 hours by MTS-based assay.
2.9. In Vivo Study of the Antiangiogenesis Eﬀects of VEGF165b.
To verify the eﬀects of VEGF165b on angiogenesis, 105 Tpr-
Met Fr3T3 ﬁbroblast cells mixed with 250μlo fs e r u m -
depleted Matrigel (Becton Dickinson Labware, Bedford,
MA) were injected subcutaneously on the ﬂanks of 5-week-
old female nude mice (Charles River Breeding Laboratories).
Themiceweredividedintothreegroups.Onegroupreceived
70 ± 10 VEGF165b/293 microcapsules per 100μl of PBS. The
s e c o n dg r o u pr e c e i v e d7 0± 10 parental/293 microcapsules
per 100μl of PBS and the last group were injected 100μl
of PBS. The microcapsules were injected at the same side
as matrigel plug. After 9 days, the mice were sacriﬁced and
Matrigel plugs were retrieved from the animals to visualize
the presence of microvessels.
3. Results
3.1. Expression of VEGF165b from Transfected Cells. Trans-
fectedcellswerecloneisolatedasdescribedabove.Theclones
were analyzed for VEGF165bp r o d u c t i o nb yw e s t e r nb l o ta n d
SDS-PAGE electrophoresis. Five positive clones were selected
from screening 35 clones. They all had positive bands with
various intensity running at approximately around 30kDa
as expected for VEGF165b .T h eﬁ n a lv e r i ﬁ c a t i o no fp r o t e i n
expression of isolated clones was performed using ELISA kit
and the clone with highest protein production was selected
(clone F10).
3.2. Morphological Studies and Viability of Encapsulated Cells.
Results showed that microcapsules with a diameter of 500 ±
50μm could be prepared. The cells were evenly distributed
within the microcapsules. The cells created colonies within
the microcapsules and then the colonies enlarged and ﬁlled
up most of the interior space of the microcapsules. Growth
and viability of encapsulated cells were analyzed using MTS
assay. Results showed that the encapsulated cells grew over
a 13–16-day period after microencapsulation, at this time
the viable cell density reached approximately 1 × 104 ±
1000/microcapsule. Then, the viability of encapsulated cells
decreasedslowlyuntilday28oftheexperiment. Theviability
of encapsulated cells was compared with nonencapsulated
cells. Nonencapsulated cells showed similar growth pattern
to encapsulated cells. Nonencapsulated cells proliferated
from day ﬁrst to day 16. The viability of nonencapsulated
cells decreased slowly thereafter (Figure 1).
3.3. In Vitro Expression and Release of VEGF165bf r o m
EncapsulatedCells. Experimentsweredesignedtoinvestigate
production of VEGF165b by encapsulated HEK293 VEGF165b
producing cells.
Sodium dodecyl sulfate-polyacrylamide gel electro-
phoresis (SDS-PAGE) and western blot were performed to
analyze the production of VEGF165b by encapsulated cells.
The medium was harvested and fresh medium was added
every three days. The results showed that the production of
VEGF165b was detected 4 days after encapsulation and had
the highest production at day 16. The pick of VEGF165bp r o -
duction at day 16 was compatible with the cell growth curve.4 Journal of Biomedicine and Biotechnology
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Figure 1: The number of viable encapsulated and nonencapsulated
HEK293 VEGF165b producing cells determined by MTS assay.
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Figure 2: Western blot analysis of human VEGF165bp r o d u c e d
by (a) encapsulated HEK293 VEGF165b producing cells and (b)
nonencapsulated HEK293 VEGF165b producing cells.
ProductionofVEGF165bthendecreasedbetweendays19and
28. Production of VEGF165bf r o mn o n e n c a p s u l a t e dc e l l sf o l -
lowed similar pattern to that of encapsulated cells (Figure 2).
An ELISA was carried out to measure the quantity of
VEGF165bharvestedfromencapsulatedVEGF165bproducing
cells and nonencapsulated VEGF165b producing cells. The
quantityofVEGF165bincreasedfrom6.5±1.2μg/mlatday13
to13±0.96μg/mlatday16.ThelevelofVEGF165bthengrad-
ually dropped to 5±1.2μg/ml for the last 3 days period. The
highest quantity of VEGF165bs e c r e t e df r o mn o n e n c a p s u -
latedcellswas14.2±0.84and15±1.8atda y16and19respec-
tively.Thevaluesthendroppedto7±0.8atday28(Figure3).
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Figure 3: The quantity of secreted VEGF165b from encapsulated
and nonencapsulated HEK293 VEGF165b producing cells deter-
mined by ELISA.
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Figure 4: The eﬀects of VEGF and VEGF165bo nH U V E C s
proliferation. The cells received 25ng/ml VEGF, 25ng/ml VEGF
and two-fold puriﬁed VEGF165b or 25ng/ml VEGF and two-fold
harvested VEGF165b from microencapsulated HEK293 VEGF165b
producing cells after overnight starving from serum and growth
factors. HUVEC proliferation was determined after 72 hours by
MTS-based assay. Puriﬁed VEGF165b and harvested VEGF165bf r o m
encapsulated HEK293 VEGF165b producing cells oﬀered similar
results in inhibition of cell proliferation, n = 3, P = .06.
3.4. In Vitro Bioactivity Assay of VEGF165bE x p r e s s e df r o m
Encapsulated Cells. The eﬀects of human VEGF165bp r o -
duced by encapsulated cells on endothelial cells were evalu-
ated using HUVECs proliferation assay. Results showed that
additionofVEGFtothecellsenhancedHUVECproliferation
and viability in a dose-dependent manner. VEGF165bp r o -
duced by encapsulated and nonencapsulated cells prevented
cell proliferation with the presence of VEGF. In the control
group of cells in which no VEGF was added, no viability
was observed. The highest endothelial cell proliferation wasJournal of Biomedicine and Biotechnology 5
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Figure 5: Tumor angiogenesis eﬀects microencapsulated HEK293 VEGF165b producing cells in experimental nude mice. Top and bottom
reprentative sample of (a) Matrigel plugs with microcapsules containing HEK293 VEGF165bp r o d u c i n gc e l l s ,( b )M a t r i g e lp l u g sw i t h
microcapsules containing parental HEK293 cells, and (c) matrigel plugs with vehicle (PBS).
observed by adding 25ng/ml VEGF. At this point, puriﬁed
VEGF165b, and harvested VEGF165b presented the highest
antagonistic eﬀects. The number of cells lessened from 1 ×
104 ± 2000 cells with VEGF to 3700 ± 140 cells with VEGF
and puriﬁed VEGF165b and to 3900 ± 50 cells with VEGF
and harvested VEGF165b from encapsulated cells. Higher
concentration of VEGF from 50 to 200ng/ml had less eﬀect
on increasing HUVECs proliferation. Similarly HUVECs
proliferation was less aﬀected with higher concentration
of VEGF165b, 400ng/ml. Puriﬁed VEGF165b and harvested
VEGF165b from encapsulated cells oﬀered similar results in
inhibition of cell proliferation (Figure 4).
3.5. Inhibition of Angiogenesis by VEGF165b. The in vivo
experiment was designed to observe the eﬀects of VEGF165b
produced by encapsulated cells on angiogenesis in tumors.
Tumor cells mixed with matrigel were s.c. injected to nude
mice as described above. Photographs of retrieved matrigel
plugs from animals showed tumor angiogenesis (Figure 5).
Use of encapsulated VEGF165b producing cells in tumor site
signiﬁcantly decreased total vascular density. The number
of vessels around the tumor with microcapsules containing
VEGF165b producing cells reduced compared to the ones
with microcapsules containing parental HEK293 cells and
matrigel control vehicle, which indicated the release of
VEGF165bf r o me n c a p s u l a t e dc e l l sa n de ﬀects of VEGF165b
on prevention of angiogenesis.
4. Discussion
Inhibition of angiogenesis has been broadly documented
as a promising approach for cancer treatment [34]. This
therapy oﬀers several advantages over the conventional
cancer therapy. For instance, one approved angiogenesis
inhibitor can be used in diﬀerent types of tumors, as solid
tumors are angiogenesis dependent. Antiangiogenesis targets
endothelial cells, which are genetically stable compared to
tumor cells, therefore, drug resistant occurs rarely. Further-
more, it has fewer systemic side eﬀects since angiogenesis
has limited actions in adults. To establish an eﬃcient
angiogenesis therapy, recently diﬀerent strategies have been
studied to block VEGF pathway. VEGF is upregulated in the
majority of human cancers, so it is known as a valid target
for antiangiogenic therapy [6]. This certainty has led the
cancer research to focus on the development of the drugs
inhibitingVEGFactivity[3,35].Inthisstudy ,wein vestigated
theeﬃcacyoftheencapsulated-producingcellsforproviding
constant release of VEGF165b. VEGF165b binds to VEGFR2,
the main VEGF receptor in angiogenesis; therefore it can
narrowly target angiogenesis activation in tumor.
VEGF165b is considered as an endogenous angiogenesis
inhibitor as it can be expressed in normal human tissues.
Increasing endogenous inhibitors has been appeared to be a
safe and reliable approach in long-term cancer therapy [36].
For example, overexpression of endostatin, an endogenous
angiogenesis inhibitor with broad spectrum has appeared to
slowdown tumorgrowth inmice[34,37].Overexpression of
VEGF165b has been also shown to inhibit growth of sarcoma,
renal, prostate [38], and colorectal cancer in mice [39].
In the current study, the eﬃcacy of encapsulated
VEGF165b producing cells for antiangiogenesis therapy was
evaluated.Encapsulationofproducingcellspromisesprovid-
ing the sustained release of the protein required for long-
term treatments in tumor suppression [40]. Slow release
of protein from engineered cells via encapsulation has6 Journal of Biomedicine and Biotechnology
been applied in various diseases including antiangiogenic
cancer therapy [41–43]. Microencapsulation of VEGF165b
producing cells showed that the cells were able to survive
and release protein throughout the period of the experiment
providing the slow release of VEGF165b. The bioactivity
of the released protein on HUVECs proliferation was also
studied. HUVECs proliferation was clearly promoted in the
presence of VEGF. The highest eﬀect of VEGF was observed
at the concentration of 25ng/ml. At this concentration of
VEGF, VEGF165b harvested from encapsulated cells oﬀered
approximately highest proliferation inhibition. Being a com-
petitive antagonist of VEGF, the concentration of VEGF165b
at each point was two-fold more than VEGF to induce the
antagonistic eﬀects. Furthermore, reducing microvessels in
tumor site after injection of microencapsulated VEGF165b
producing cells in animals veriﬁed the eﬃcacy of this system
to maintain the cells alive and able to produce the desired
protein in vivo. Although these ﬁnding are encouraging in
cancer treatment, there are still numerous unanswered ques-
tions that have to be revealed in order to obtain a practical
approach to suppress tumors including the accurate dosage
of an angiogenic inhibitor, the length of treatment, and the
eﬃcacy of combination therapy that need further analysis.
Delivery of VEGF165b by encapsulated HEK293
VEGF165b producing cells reveals the potential of cell
microencapsulation for sustained release of VEGF165b. Cell
microencapsulation can be applied for continuous release of
bioactive therapeutic proteins for medical purposes.
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